<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00556621</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000574107</org_study_id>
    <secondary_id>CLCC_GEMCIRAV</secondary_id>
    <secondary_id>INCA-RECF0285</secondary_id>
    <secondary_id>GETUG-CLCC-GEMCIRAV</secondary_id>
    <nct_id>NCT00556621</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer</brief_title>
  <acronym>GEMCIRAV</acronym>
  <official_title>Phase 1-2 Study of the Association of Gemzar ® - Cisplatin-concurrent Radiotherapy in Patients With Non-metastatic Tumors of the Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe D'Etude des Tumeurs Uro-Genitales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination
      chemotherapy together with radiation therapy may kill more tumor cells.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of gemcitabine when
      given together with cisplatin and radiation therapy and to see how well they work in treating
      patients with stage II or stage III bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the incidence and nature of acute and late toxicity of gemcitabine
           hydrochloride, cisplatin, and concurrent radiotherapy in patients with stage II or III
           transitional cell carcinoma of the bladder. (Phase I)

        -  Determine the efficacy of this regimen, in terms of local tumor control (absence of
           local progression), in these patients. (Phase II)

      Secondary

        -  Determine the maximum tolerated dose and the recommended phase II dose of gemcitabine
           hydrochloride when administered with cisplatin and radiotherapy in these patients.
           (Phase I)

        -  Assess the 5- and 10-year survival and the progression-free survival of patients treated
           with this regimen. (Phase II)

        -  Assess the quality of life of patients treated with this regimen. (Phase II)

      OUTLINE: This is a phase I, dose-escalation study of gemcitabine hydrochloride followed by a
      phase II, multicenter study.

      Patients receive gemcitabine hydrochloride IV over 30 minutes twice weekly for 5 weeks and
      cisplatin IV continuously over 4 days on days 2-5 and 23-26 (weeks 1 and 4). Patients also
      undergo radiotherapy once daily 5 days a week for 5 weeks.

      Three weeks after completion of treatment, patients undergo cystoscopy and transurethral
      resection (TUR). Patients with residual tumor or disease progression undergo radical TUR.
      After surgery, patients who achieve a complete response receive gemcitabine hydrochloride IV
      twice weekly for 2 weeks and cisplatin IV continuously over 4 days in week 1. Patients also
      undergo radiotherapy once daily 5 days a week for 2 weeks.

      After completion of study treatment, patients are followed at 6-8 weeks and then 6 months
      thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of acute and late toxicity (Phase I)</measure>
    <time_frame>From baseline to the end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Local tumor control (Phase II)</measure>
    <time_frame>From baseline to the end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose and recommended phase II dose of gemcitabine hydrochloride when administered with cisplatin and radiotherapy (Phase I)</measure>
    <time_frame>From baseline to the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5- and 10-year survival (Phase II)</measure>
    <time_frame>until 5 and 10 year after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (Phase II)</measure>
    <time_frame>6 to 8 weeks after to the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (Phase II)</measure>
    <time_frame>From baselin to the end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>gemcitabine, cisplatine, radiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>gemcitabine, cisplatine, radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>gemcitabine, cisplatine, radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <arm_group_label>gemcitabine, cisplatine, radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cystoscopy</intervention_name>
    <arm_group_label>gemcitabine, cisplatine, radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>gemcitabine, cisplatine, radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>gemcitabine, cisplatine, radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of muscle invasive transitional cell carcinoma of the bladder

               -  T2-4a, N0, M0 (stage II or III disease)

          -  No adenocarcinoma or squamous cell carcinoma

        PATIENT CHARACTERISTICS:

          -  WHO performance status (PS) 0-2 or Karnofsky PS 70-100%

          -  Life expectancy ≥ 6 months

          -  ANC ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 10 g/dL

          -  Creatinine clearance ≥ 60 mL/min

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for at least 2 months
             after completion of study treatment

          -  No other prior malignancy, except previously treated nonmalignant skin cancer or
             carcinoma in situ of the cervix

          -  No prior serious digestive complications (e.g., ulcerative colitis or complicated
             diverticulosis)

        PRIOR CONCURRENT THERAPY:

          -  No prior radiotherapy or chemotherapy (except for intravesical instillations)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Azria, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut du Cancer de Montpellier - Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2007</study_first_submitted>
  <study_first_submitted_qc>November 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2007</study_first_posted>
  <last_update_submitted>July 29, 2015</last_update_submitted>
  <last_update_submitted_qc>July 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

